Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Amy Poehler's podcast is a hit. It's also a Trojan horse for talking about women and aging. - 26 Travel Services for Colorful Get-aways: Pick Your Fantasy Escape
- 3Turkey key underlying issue as Israel, Greece, Cyprus hold summit
- 475% of US adults may meet criteria for obesity under new definition, study finds
- 5A Manual for Well known Western television Series
- Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- Czech Republic's new premier: No money for Ukraine
- JFK's granddaughter reveals terminal cancer diagnosis, criticizes cousin RFK Jr.
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- Shipping: The Corridors of Trade and the Coming of Another Period
- The Best Web-based Courses for Expertise Improvement
- Hand Skin Is Additionally Significant - What You Ought to Realize About Hand Cream
- Dark matter may be made of pieces of giant, exotic objects — and astronomers think they know how to look for them
